Table 4.
Treatment-related adverse events reported in >3 patients treated with PF-06647263 QW
| Adverse event n (%) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | Total N = 35 |
|---|---|---|---|---|---|---|
| Any AE | 8 (22.9) | 13 (37.1) | 6 (17.1) | 1 (2.9)1 | 1 (2.9) | 29 (82.9) |
| Fatigue | 10 (28.6) | 6 (17.1) | 2 (5.7) | 0 (0.0) | 0 (0.0) | 18 (51.4) |
| Nausea | 10 (28.6) | 7 (20.0) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 18 (51.4) |
| Vomiting | 11 (31.4) | 3 (8.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 14 (40.0) |
| Mucosal inflammation | 10 (28.6) | 2 (5.7) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 13 (37.1) |
| Thrombocytopenia | 6 (17.1) | 3 (8.6) | 2 (5.7) | 0 (0.0) | 0 (0.0) | 11 (31.4) |
| Diarrhea | 8 (22.9) | 2 (5.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 10 (28.6) |
| Decreased appetite | 5 (14.3) | 4 (11.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 9 (25.7) |
| Dysgeusia | 5 (14.3) | 3 (8.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 8 (22.9) |
| Alopecia | 5 (14.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (14.3) |
| Asthenia | 2 (5.7) | 2 (5.7) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 5 (14.3) |
| Dry skin | 4 (11.4) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (14.3) |
| Anemia | 2 (5.7) | 2 (5.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (11.4) |
| Nail disorder | 4 (11.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (11.4) |
| Pruritus | 4 (11.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (11.4) |
| Pyrexia | 4 (11.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (11.4) |
| Skin discoloration | 3 (8.6) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (11.4) |
1
One patient experienced grade 4 gastritis.
Abbreviations: AE, adverse event; QW, every week.